5-氨基酮戊酸光动力疗法联合人干扰素α-2β治疗尖锐湿疣的效果分析

Efficacy of 5-Aminolaevulinic acid photodynamic therapy combined with human interferon α-2β in the treatment of condyloma acuminatum

  • 摘要:
    目的 探讨5-氨基酮戊酸光动力疗法(ALA-PDT)联合人干扰素α-2β治疗尖锐湿疣(CA)的效果及对血清T细胞亚群和趋化因子配体19(CCL19)、基质金属蛋白酶-3(MMP-3)水平的影响。
    方法 选择86例CA患者为研究对象,根据随机数字表法将CA患者分为对照组(ALA-PDT治疗)和观察组(ALA-PDT联合人干扰素α-2β治疗),每组43例。比较2组患者临床疗效以及治疗前后血清T细胞亚群、CCL19、MMP-3水平变化情况,并记录治疗期间不良反应发生情况。随访6个月,记录复发疣体数量和复发率。
    结果 观察组治疗总有效率高于对照组,差异有统计学意义(P < 0.05); 治疗后,观察组CD4+、CD8+、CD4+/CD8+较对照组升高, 差异有统计学意义(P < 0.05)。与对照组比较,观察组治疗后血清CCL19升高, MMP-3下降,差异有统计学意义(P < 0.05)。2组不良反应发生率比较,差异无统计学意义(P>0.05)。对照组复发率、平均复发疣体数量高于观察组,差异有统计学意义(P < 0.05)。
    结论 ALA-PDT联合人干扰素α-2β治疗尖锐湿疣效果显著,可调节血清T细胞亚群水平,降低MMP-3水平,提升CCL19水平,且安全性较好。

     

    Abstract:
    Objective To investigate the therapeutic effects of 5-Aminolaevulinic acid photodynamic therapy (ALA-PDT) combined with human interferon α-2β in the treatment of condyloma acuminatum (CA) and its impacts on serum T-cell subsets, chemokine ligand 19 (CCL19), and matrix metalloproteinase-3 (MMP-3) levels.
    Methods A total of 86 patients with CA were enrolled and randomly divided to control group (treated with ALA-PDT alone) and observation group (treated with ALA-PDT combined with human interferon α-2β), with 43 patients in each group. Clinical efficacy, changes in serum T-cell subsets, CCL19, and MMP-3 levels before and after treatment were compared between the two groups. Adverse reactions during treatment were recorded. Patients were followed up for 6 months to record the number of warts and recurrence rate.
    Results The total effective rate of treatment in the observation group was significantly higher than that in the control group (P < 0.05). After treatment, the levels of CD4+, CD8+, and CD4+/CD8+ in the observation group were significantly elevated compared to the control group (P < 0.05). Additionally, serum CCL19 levels increased, while MMP-3 levels decreased in the observation group post-treatment compared to the control group (P < 0.05). No significant difference was observed in the incidence of adverse reactions between the two groups (P>0.05). The recurrence rate and the number of average recurrent warts were significantly higher in the control group than in the observation group (P < 0.05).
    Conclusion The combination of ALA-PDT and human interferon α-2β exhibits remarkable efficacy in the treatment of CA, which can effectively regulate serum T-cell subset levels, reduce MMP-3 levels, enhance CCL19 levels, and demonstrates good safety.

     

/

返回文章
返回